Hound Partners, LLC Coherus Bio Sciences, Inc. Transaction History

Hound Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $9.6 Million - $12.7 Million	-665,444 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$11.67 - $22.53 $5.14 Million - $9.92 Million	-440,429 Reduced 39.83%	665,444 $10.8 Million
Q3 2019 Nov 14, 2019	SELL	$16.3 - $23.37 $7.73 Million - $11.1 Million	-474,154 Reduced 30.01%	1,105,873 $22.4 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $4.97 Million - $8.38 Million	-379,291 Reduced 19.36%	1,580,027 $34.9 Million
Q1 2019 May 15, 2019	SELL	$8.38 - $15.5 $481,925 - $891,389	-57,509 Reduced 2.85%	1,959,318 $26.7 Million
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $56,666 - $106,650	6,551 Added 0.33%	2,016,827 $18.3 Million
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $17.8 Million - $24.9 Million	1,231,768 Added 158.22%	2,010,276 $33.2 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $7.98 Million - $13.6 Million	778,508 New	778,508 $10.9 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $85.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Hound Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Hound Partners, LLC with notifications on news.